VERA Vera Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
• • Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments

Risk Factors

• • No newly added risk factor this quarter; risks consistent with prior 10-K filing
• • Material update on financing: $497.4M cash and marketable securities as of Sept 30, 2025, sufficient to fund operations beyond 12 months but capital needs remain high

What are the latest VERA SEC filings in 2026?

Vera Therapeutics, Inc. (VERA) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VERA file its most recent 10-K annual report?

Vera Therapeutics, Inc. (VERA) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VERA 10-Q quarterly reports?

Vera Therapeutics, Inc. (VERA)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every VERA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VERA filed recently?

Vera Therapeutics, Inc. (VERA)'s most recent 8-K was filed on March 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VERA insider trading activity (Form 4)?

SignalX aggregates every VERA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VERA file with the SEC?

Vera Therapeutics, Inc. (VERA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VERA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vera Therapeutics, Inc. (VERA).

What is VERA's SEC CIK number?

Vera Therapeutics, Inc. (VERA)'s SEC CIK (Central Index Key) number is 1831828. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1831828 to look up all VERA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VERA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Vera Therapeutics, Inc. (VERA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.